Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases
Overall Portfolio Of 11 Products Includes Three From Two Unnamed Firms
Executive Summary
Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.